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Abstract 
Background: The pharmacodynamic effects of changing from standard-dose clopidogrel to 
low-dose (3.75 mg) prasugrel in Japanese patients are largely unknown. 
Methods and Results: A total of 53 consecutive Japanese patients with stable coronary artery 
disease (CAD) who received aspirin and clopidogrel were enrolled. Clopidogrel was switched 
to 3.75 mg prasugrel. At day 14, prasugrel was switched to 75 mg clopidogrel. Platelet reactivity 
was measured using the VerifyNow assay at baseline, day 14, and day 28. VerifyNow P2Y12 
reaction units (PRU) >208 was defined as high on-treatment platelet reactivity (HPR). The 
prevalence of HPR (18.9% vs. 41.5% vs. 44.2%, P<0.001) and the PRU level (154.3±54.2 vs. 
196.2±55.5 vs. 194.6±55.8, P<0.001) were significantly lower on prasugrel maintenance 
therapy compared with the clopidogrel therapy before and after switching. The CYP2C19 
genotypes that account for the 3 phenotypes (ie, extensive metabolizer, intermediate 
metabolizer, and poor metabolizer) had a significant impact on platelet reactivity with 
clopidogrel (174.9±54.0 vs. 193.1±56.5 vs. 240.6±25.4 PRU, P<0.001) but not prasugrel 
(147.0±51.9 vs. 147.5±58.3 vs. 184.4±38.3 PRU, P=0.15). 
Conclusions: Low-dose prasugrel achieves stronger platelet inhibition than clopidogrel in 
Japanese patients with stable CAD. (Circ J 2015; 79: 2439 – 2444) 
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High on-treatment platelet reactivity (HPR) is associated with adverse cardiovascular events 
including stent thrombosis in patients undergoing percutaneous coronary intervention (PCI).1–
9 The interpatient variability in the pharmacodynamics response to clopidogrel is well 
recognized, 10–13 and patients with coronary artery disease (CAD) 
with a lower degree of platelet inhibition in response to clopidogrel have been shown to be at 
increased risk of cardiovascular events.1–9 Prasugrel is a third-generation thienopyridine that 
achieves greater platelet inhibition with less variability between patients than does 
clopidogrel.14 Considering the higher average age, lower body weight, and increased bleeding 
risk with other thrombotic agents in Japanese patients compared with Western patients,15 the 
maintenance dose of prasugrel in Japanese patients was determined as approximately one-third 
that used in Western patients (3.75 mg vs. 10 mg). The pharmacodynamics effects of changing 
from 75 mg clopidogrel to 3.75 mg prasugrel in Japanese patients undergoing coronary stenting, 
however, are largely unknown.  
 
Methods 
Study Design and Patients 
This study was a single-center, prospective, open-label study designed to evaluate antiplatelet 
effect when clopidogrel was switched to prasugrel in patients undergoing PCI. Patients were 
eligible for the study if they were between 20 and 80 years of age and had daily aspirin and 
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clopidogrel for ≥14 days before or after PCI for stable CAD. Patients were excluded in the 
presence of any of the following: acute coronary syndrome (ACS) event, PCI, or coronary artery 
bypass graft surgery within the previous 4 weeks, contraindications to prasugrel, severe liver 
dysfunction, severe renal insufficiency, body weight ≤50 kg, platelet count ≤10×104, and 
pregnancy. Patients were also excluded if they received other anti-thrombotic agents and were 
at high risk of bleeding. 
A flow chart of the study is shown in Figure 1. Patients who received aspirin (100 mg 
daily) and clopidogrel (75 mg daily) for ≥14 days underwent platelet function test. Clopidogrel 
was switched to 3.75 mg prasugrel (maintenance dose in Japanese patients). Platelet reactivity 
measurement and safety evaluation were done on outpatient visit on day 14. Direct switching 
from prasugrel to 75 mg clopidogrel was then performed without an intervening washout period. 
At day 28, patients returned for clinical and laboratory assessment as performed on the day 14 
visit. Aspirin and other medications remained unchanged throughout the study period. Platelet 
function was assessed using the VerifyNow assay (Accumetrics, San Diego, CA, USA).16 This 
measures adenosine diphosphate-induced platelet function, reported as P2Y12 reaction units 
(PRU). Based on previous studies in which thresholds for platelet reactivity were identified,8 
VerifyNow P2Y12 >208 PRU was defined as HPR.  
The protocol was approved by the institutional review boards at Chiba University 
Hospital and the study was conducted in accordance with regulatory standards and ethics 
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guidelines for clinical studies according to the Declaration of Helsinki. All patients provided 
written informed consent. The independent data center of Chiba University Hospital collected 
and managed data. The present study was registered at the University Hospital Medical 
Information Network Clinical Trials Registry (number: UMIN 000014528) in Japan. 
 
CYP2C19 Genotyping 
Genotyping of CYP2C19*2 (rs4244285, c681G>A) and CYP2C19*3 (rs4986893, c636G>A) 
was performed using the newly developed genotyping system, GTS-7000 (Shimadzu, Kyoto, 
Japan), with 1 μl of the rest of whole blood used for laboratory testing. This system detects 
single-nucleotide polymorphisms on direct polymerase chain reaction amplification with no 
requirement for DNA extraction. The patients were classified into 3 genotype groups: extensive 
metabolizer (EM) (*1/*1), intermediate metabolizer (IM) (*1/*2 or *1/*3), and poor 
metabolizer (PM) (*2/*2, *2/*3 or *3/*3). The use of blood samples for genotyping was 
approved (approval No. 511) by the Biomedical Research Ethics Committee of the Graduate 
School of Medicine, Chiba University, in accordance with the Ethics Guidelines for Human 
Genome and Gene Analyses Research in Japan. 
 
Study Endpoints 
The primary efficacy endpoint was comparison of the prevalence of HPR between clopidogrel 
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treatment at study entry and prasugrel maintenance treatment. Additional endpoints included 
the prevalence of HPR and PRU level between clopidogrel treatment at study entry, prasugrel 
maintenance treatment, and clopidogrel therapy at last follow-up. PRU level with clopidogrel 
and prasugrel treatment was also compared among the 3 CYP2C19 polymorphism groups. The 
safety endpoints were the frequency of bleeding events according to the Thrombolysis in 
Myocardial Infarction (TIMI) bleeding criteria, definite or probable stent thrombosis according 
to the Academic Research Consortium definition,17 and myocardial infarction according to the 
Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) criteria during the 
study period.18 
 
Statistical Analysis 
Based on previous studies,8,19 we estimated the rate of HPR as 40% on clopidogrel therapy and 
10% on prasugrel therapy. On the basis of these assumptions, we estimated that 53 patients 
were required for a power of 90% and a 2-sided α level of 0.05, assuming a dropout rate of 10%.  
Continuous variables are presented as mean ± SD and were compared using paired or 
unpaired Student’s t-test, or analysis of variance (ANOVA) as appropriate. Categorical 
variables are presented as n (%) and were compared using McNemar test. Statistical analysis 
was performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). P<0.05 was considered 
significant. 
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Results 
From July 2014 through November 2014, 53 patients were enrolled. All patients underwent 
platelet function tests at 3 time points except 1 patient, who did not receive the last platelet 
function test. Patient characteristics are listed in Table 1. There were no adverse cardiovascular 
events or side-effects of clopidogrel or prasugrel, except 1 case of urticaria during prasugrel 
treatment. 
The prevalence of HPR (Figure 2) and PRU level (Figure 3) were significantly lower 
on prasugrel maintenance therapy compared with clopidogrel therapy before and after 
switching. Figure 4 shows patient number and percentage of HPR and non-HPR at 3 time points. 
Of 22 patients with HPR on clopidogrel therapy, 13 (59.1%) had non-HPR after prasugrel 
treatment. HPR, however, was observed in 9 patients (40.9%) even on prasugrel maintenance 
treatment. All patients who had non-HPR on clopidogrel before switching, also had non-HPR 
after prasugrel treatment, except 1 (3.2%). Table 2 lists CYP2C19 genotype. The genotypes of 
CYP2C19 polymorphism had a significant impact on platelet reactivity with clopidogrel 
(Figure 5A). In contrast, there was no significant difference in platelet reactivity with prasugrel 
among the 3 genotype groups of CYP2C19 polymorphism (Figure 5B). 
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Discussion 
To the best of our knowledge, this is the first study assessin platelet reactivity after switching 
from clopidogrel to prasugrel in Japanese patients with stable CAD. The prevalence of HPR 
and PRU level were significantly lower on prasugrel maintenance therapy compared with 
clopidogrel therapy. CYP2C19 polymorphism genotype had a significant impact on platelet 
reactivity with clopidogrel but not prasugrel. These findings are consistent with those of 
previous Western studies.19–22 The SWitching Anti Platelet (SWAP) study evaluated platelet 
inhibition after switching from 75 mg maintenance clopidogrel to 10 mg prasugrel. Platelet 
function was significantly lower with prasugrel compared with clopidogrel.20 The Testing 
platelet Reactivity In patients underGoing elective stent placement on clopidogrel to Guide 
alternative thErapy with pRasugrel (TRIGGER-PCI) trial investigated the efficacy, safety, and 
antiplatelet effect of prasugrel as compared with clopidogrel in patients with HPR (PRU >208) 
after elective PCI.19 Even in patients with HPR, prasugrel significantly decreased median PRU, 
from 245 (IQR, 225–273) to 80 (IQR, 42–124). Furthermore, 176 patients in the prasugrel arm 
(94.1%) reached PRU ≤208.  
The TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet 
InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) 
compared prasugrel with clopidogrel in patients with moderate-to-highrisk ACS who 
underwent PCI.23 The primary efficacy endpoint, defined as death from cardiovascular causes, 
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non-fatal myocardial infarction, or non-fatal stroke, occurred in 12.1% of patients receiving 
clopidogrel and in 9.9% of patients receiving prasugrel (P<0.001). Major bleeding, however, 
was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving 
clopidogrel (P=0.03). Considering the higher average age, lower body weight, and increased 
bleeding risk with other thrombotic agents in Japanese patients compared with Western patients, 
meticulous dose-finding was performed. Based on the Japanese Phase II trial,24 prasugrel 
loading and maintenance dose in Japanese patients were determined as 20 mg and 3.75 mg, 
respectively. The PRASugrel compared with clopidogrel For Japanese patIenTs with Acute 
Coronary Syndrome undergoing PCI (PRASFIT-ACS) study and the PRASugrel compared 
with clopidogrel For Japanese patIenTs with CAD undergoing Elective PCI (PRASFIT-
Elective) study showed usefulness of this low-dose prasugrel in Japanese patients.25,26 The 
present study showed that this low dose prasugrel achieved greater inhibition of platelet 
function than standard-dose clopidogrel. 
The Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-
DES) registry evaluated the effect of HPR on clinical outcome in patients who received aspirin 
and clopidogrel after drug-eluting stent implantation.8 HPR on clopidogrel was strongly related 
to stent thrombosis and myocardial infarction and was inversely related to bleeding. Esterases 
shunt the majority of clopidogrel to a dead-end inactive pathway, with the remaining prodrug 
requiring a 2-step metabolic transformation before binding to the platelet P2Y12 adenosine 
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diphosphate receptor. The conversion of clopidogrel to its active metabolite is regulated by the 
CYP450 system, and the type of genetic polymorphism partly determines the extent to which 
clopidogrel inhibits adenosine diphosphate-induced platelet activation.27 Clopidogrel resistance 
has been reported to range between 16 and 50%.28 Prasugrel is an inactive prodrug that is 
transformed first through hydrolization by esterases, followed by a single CYP-dependent 
oxidative step into its active metabolite.27 Common functional CYP variants do not affect active 
drug metabolite level or inhibition of platelet aggregation in patients treated with prasugrel.  
Prasugrel resistance does exists, although it is less frequent compared with clopidogrel 
resistance. The possible mechanisms of prasugrel resistance are poor patient adherence, 
variations in the absorption of the prodrug and generation and clearance of the active metabolite, 
differences in receptor expression and post-receptor signaling pathway, and P2Y12 receptor 
polymorphisms. Prasugrel resistance has been reported to range between 0 and 11.5%.29,30 In 
the present study, it was observed in 18.9% of patients. This may be associated with the lower 
maintenance dose of prasugrel in Japanese patients. Post-hoc analysis of the PRASFIT-ACS 
study showed 262 PRU as the optimal cut-off for major adverse cardiovascular events in 
Japanese patients with ACS.31 We analyzed the prevalence of HPR using PRU >262 as the 
definition of HPR. This was 11.3% at baseline clopidogrel therapy, 0% after switching to 
prasugrel, and 11.5% after switching to clopidogrel (P=0.02). In the TaRgeted platelet 
Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes 
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(TRILOGY ACS) trial, the maintenance dose was 10 mg in patients <75 years who weighed 
≥60 kg, and 5 mg for those aged ≥75 years, and those <75 years with body weight <60 kg.32 In 
patients aged <75 years and with body weight ≥60 kg, median PRU at 30 days was 64 (IQR, 
33–128). In patients aged <75 years with body weight <60 kg, median 30-day PRU was 139 
(IQR, 86–203). In patients aged ≥75 years, median PRU was 164 (IQR, 105–216).32 Neubauer 
et al showed that doubling of the 10 mg maintenance dose of prasugrel was effective, with 
adequate platelet inhibitory effect and without bleeding events in all 4 patients with prasugrel 
resistance.33 Use of a 3.75 mg prasugrel maintenance dose is a safe approach in Japanese 
patients, but it may be effective to increase prasugrel to ≥5 mg in patients with HPR on 3.75 
mg prasugrel. Further studies are required to evaluate the safety and efficacy of higher doses of 
prasugrel in patients with HPR on 3.75 mg prasugrel. 
 
Study Limitations 
First, the present study was not a cross-over study. Second, it was a pharmacodynamics 
study and was not sized to assess efficacy or safety. Therefore, it was not designed to determine 
whether cardiovascular thrombotic events would decrease after switching from clopidogrel to 
prasugrel. Third, based on previous Western studies, HPR was defined as PRU >208. Recently, 
on post-hoc analysis of the PRASFIT-ACS study, PRU >262 was identified as the cut-off to 
predict major cardiovascular events after PCI in Japanese patients with ACS.30 The present 
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study, however, enrolled patients with stable CAD, and the optimal PRU cut-off in Japanese 
patients with stable CAD is unknown. 
 
Conclusions 
Low-dose prasugrel achieves stronger platelet inhibition than clopidogrel in Japanese patients 
with stable CAD who undergo stent implantation. Switching from clopidogrel to prasugrel may 
be a therapeutic option, especially in patients at higher risk of stent thrombosis and ischemic 
coronary events. 
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Figure legends 
Figure 1   Flow chart diagram of the study 
 
Figure 2   The prevalence of high on-treatment platelet reactivity (HPR) between clopidogrel 
treatment at study entry, prasugrel maintenance treatment, and clopidogrel therapy at the last 
follow-up. 
 
Figure 3   P2Y12 reaction units (PRU) between clopidogrel treatment at study entry, 
prasugrel maintenance treatment, and clopidogrel therapy at the last follow-up. 
 
Figure 4   Patient number and percentage of high on-treatment platelet reactivity (HPR) and 
non-HPR with clopidogrel treatment at study entry, prasugrel maintenance treatment, and 
clopidogrel therapy at the last follow-up. 
 
Figure 5   The impact of the genotypes of CYP2C19 polymorphism on platelet reactivity with 
clopidogrel (A) and prasugrel (B). EM, group with extensive metabolizer genotype; IM, group 
with intermediate metabolizer genotype; PM, group with poor metabolizer genotype; PRU, 
P2Y12 reaction unit. 
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Table 1   Patient Characteristics 
Age (years) 
Male 
Body mass index (kg/m2) 
eGFR (ml/min/1.73 m2) 
Coronary risk factors 
   Hypertension 
   Dyslipidemia 
   Diabetes 
   Current smoker 
   Family history 
Prior myocardial infarction 
Prior ischemic stroke 
Prior PCI 
Prior CABG 
Medication 
Aspirin 
   ACE inhibitors 
ARB 
   β blockers 
   Ca channel blockers 
   Statins 
   Proton pump inhibitors 
66.6  9.2 
47 (89%) 
24.3 ± 3.0 
71.7 ± 17.4 
 
37 (70%) 
40 (75%) 
21 (40%) 
8 (15%) 
12 (24%) 
18 (34%) 
2 (4%) 
53 (100%) 
2 (4%) 
 
53 (100%) 
15 (28%) 
4 (8%) 
31(58%) 
25 (47%) 
48 (91%) 
 39 (74%) 
ACE, angiotensin-converting enzyme; ARB, angiotensin II 
receptor blocker; CABG, coronary artery bypass graft; 
eGFR, estimated glomerular filtration rate; PCI, 
percutaneous coronary intervention. 
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Table 2   Distribution of CYP2C19 Genotypes 
*1/*1 
*1/*2 
*1/*3 
*2/*2 
*2/*3 
*3/*3 
17 (32.1%) 
16 (30.2%) 
10 (18.9%), 
7 (13.2%), 
3 (5.7%), 
0 (0%). 
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